Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
BMO Capital analyst Keith Tapper CFA maintains $Neurogene(NGNE.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 80.0% and a
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook
Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401
Neurogene's NGN-401 Wins Key FDA Designation
Neurogene's NGN-401 Shows Promise for Rett Syndrome
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Neurogene Analyst Ratings
Buy Rating for Neurogene Based on Strong Clinical Prospects and Technological Advantages
Express News | Neurogene Inc : H.c. Wainwright Cuts Target Price to $49 From $51
Neurogene | 10-Q: Q2 2024 Earnings Report
Buy Rating Affirmed for Neurogene Amid Promising Clinical Trials and Strategic FDA Milestones
Neoleukin Therapeutics GAAP EPS of -$1.09 Misses by $0.07, Revenue of $0.93M
Neurogene: Q2 Earnings Snapshot
Express News | Neurogene Inc: Qtrly Shr Loss $1.09
Express News | Neurogene Inc: Continues to Expect Current Cash, Cash Equivalents & Marketable Securities to Fund Operations Into H2 2026
Express News | Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Cash, Cash Equivalents and Investments as of June 30 Were $153.9M >NGNE
Neurogene 2Q Loss/Shr $1.09 >NGNE
Press Release: Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates